We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byMagnar Slettebakk
Modified over 4 years ago
Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue Li, MD, Zhen-fa Zhang, MD, PhD, Jian You, MD, PhD, Chang-li Wang, MD, PhD The Annals of Thoracic Surgery Volume 96, Issue 6, Pages (December 2013) DOI: /j.athoracsur Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Typical photomicrographs show expression of osteopontin (OPN) and CD44 immunohistochemistry in tissue microarray. Diaminobenzidine solution is the stain used in all images. (A) OPN+ (original magnification × 40); (B) OPN+ (original magnification ×100); (C) OPN– (original magnification ×40); (D) OPN– (original magnification ×100; (E) CD44v6+ (original magnification ×40); (F) CD44v6+ (original magnification ×100); (G) CD44v6– (original magnification ×40); and (H) CD44v6– (original magnification ×100). The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Prognostic significance assessed using Kaplan-Meier survival estimates and log-rank tests. Comparisons are shown of overall survival and disease-free survival (DFS) by (A and B) osteopontin (OPN) and (C and D) CD44v6. The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions
Fig 3 Kaplan-Meier analysis of (A) overall survival and (B) disease-free survival for combined osteopontin (OPN) and CD44v6. The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions
Fig 4 Kaplan-Meier analysis shows (A) overall survival and (B) disease-free survival for combined osteopontin (OPN) and CD44v6 in non-small cell lung cancer patients at stage I. The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions
Elizabeth A. David, MD, David T
Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L
Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,
Treating Constrictive Pericarditis in a Chinese Single-Center Study: A Five-Year Experience Yiyun Lin, MD, Mi Zhou, MMS, Jian Xiao, MD, Bin Wang, MD,
Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.
Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer
Thomas J. Birdas, MD, Richard P. M
Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer Chukwumere E. Nwogu, MD, Adrienne Groman, MA, Daniel.
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,
Rodrigo A. S. Sardenberg, MD, Clovis Pinto, MD, Cynthia A
Chun Chieh Lin, PhD, MBA, Matthew P
Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non- Small Cell Lung Cancer Matthew P. Smeltzer, PhD, Nicholas Faris, MDiv,
Joshua E. Rosen, BASc, Hari B
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.
Amiodarone Significantly Decreases Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Lars P. Riber, MD, PhD, Thomas D. Christensen,
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD
Log Odds of Positive Lymph Nodes Predicts Survival in Patients After Resection for Esophageal Cancer Jinlin Cao, MD, Ping Yuan, MD, Honghai Ma, MD, Peng.
Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma Wencheng Zhang, MD, Hongxia Zhu, MD, Xiao.
© 2023 SlidePlayer.com Inc. All rights reserved.